Balsalazide
Clinical data | |
---|---|
Trade names | Colazal, Giazo |
AHFS/Drugs.com | Monograph |
MedlinePlus | a699052 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | <1% |
Protein binding | ≥99% |
Elimination half-life | 12hr |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Balsalazide is an anti-inflammatory drug used in the treatment of inflammatory bowel disease. It is sold under the brand names Giazo, Colazal in the US and Colazide in the UK. It is also sold in generic form in the US by several generic manufacturers.
It is usually administered as the disodium salt. Balsalazide releases
disease-modifying antirheumatic drugs (DMARDs) family of medications.[3] It is unclear exactly how it works.[3]
Synthesis
Ex 3 is actually for Ipsalazide. See Ex 4 for Balsalazide proper. Same protocol but uses β-Alanine.
- Starting material is 4-aminopara-aminobenzoic acid and glycine.
- That product is then treated with diazonium salt.
- Reaction of this species with salicylic acid proceeds at the position para to the phenol to give balsalazide.
References
- ^ "Colazide 750mg Capsules - Summary of Product Characteristics (SmPC)". (emc). 3 January 2019. Retrieved 2 October 2020.
- PMID 11709512.
- ^ a b "Sulfasalazine". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
External links
- "Balsalazide". Drug Information Portal. U.S. National Library of Medicine.